Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Contribution of mutant HSC clones to immature and mature cells in MDS and CMML, and variations with AZA therapy

9 Dec 2022

Abstract excerpt

Myelodysplastic neoplasms (MDSs) and chronic myelomonocytic leukemia (CMML) are clonal disorders driven by progressively acquired somatic mutations in hematopoietic stem cells (HSCs). Hypomethylating agents (HMAs) can modify the clinical course of MDS and CMML. Clinical improvement does not require eradication of mutated cells and may be related to improved differentiation capacity of mutated HSCs. However, in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Hematopoietic Stem Cell Transplantation
Share to Myeloproliferative Neoplasms: Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36493342
DOI: 10.1182/blood.2022018602

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Contribution of mutant HSC clones to immature and mature cells in MDS and CMML, and variations with AZA therapyPMID 36493342Read ↗

Single cell genotyping of matched bone marrow and peripheral blood cells in treatment naive and AZA-treated MDS and CMMLSemantic proximity Read ↗

Single cell multiomics reveal clonal and functional dynamics of MDS stem/progenitor cells during hypomethylating therapySemantic proximity Read ↗

Mutations in myelodysplastic syndromes: Core abnormalities and CHIPping away at the edges.Semantic proximity Read ↗

Integrative Genomics Identifies the Molecular Basis of Resistance to Azacitidine Therapy in Myelodysplastic SyndromesSemantic proximity Read ↗

Targeting MCL1-driven anti-apoptotic pathways overcomes blast progression after hypomethylating agent failure in chronic myelomonocytic leukemia.Semantic proximity Read ↗

Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents.Semantic proximity Read ↗

Hematopoietic Stem Cell Heterogeneity Is Linked to the Initiation and Therapeutic Response of Myeloproliferative Neoplasms.Semantic proximity Read ↗

Multi-omics reveals azacitidine partially restores the hematopoiesis-supportive functions in mesenchymal stromal cells from patients with chronic myelomonocytic leukemiaSemantic proximity Read ↗

Distinct Patterns of Clonal Evolution Drive Myelodysplastic Syndrome Progression to Secondary Acute Myeloid Leukemia.Semantic proximity Read ↗

Single-cell mutational profiling enhances the clinical evaluation of AML MRD.Semantic proximity Read ↗

Hypomethylating agents induce epigenetic and transcriptional heterogeneity with implications for AML cell self-renewalSemantic proximity Read ↗

Single-Nucleotide Variations, Insertions/Deletions and Copy Number Variations in Myelodysplastic Syndrome during Disease Progression Revealed by a Single-Cell DNA Sequencing Platform.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.